Nico Gagelmann
@nicogagelmann.bsky.social
📤 622
📥 71
📝 44
Hematologist. Academic. Train. Think. Let's create and integral and loving actuality.
pinned post!
Finally in Boston! Honored to join
@danafarber.bsky.social
, eager to learn and contribute in this terrific community
@coleman-lindsley.bsky.social
. A place of science, purpose and hope.
about 2 months ago
1
3
0
reposted by
Nico Gagelmann
American Society of Hematology
6 days ago
Don't get left out at sea! Prepare now for ASH-a-Palooza at #ASH25🐬 ◽Sign up early for Blood Buddy speed mentoring: https://ow.ly/Cafw50XA6Gt ◽Arrive by 11:45 a.m. for the Global Hematology Trainee Networking Lunch ◽Join the AAP treasure hunt ( in the #ASH25 app) #ASHTrainee
ASH Education
0
3
1
reposted by
Nico Gagelmann
American Society of Hematology
4 days ago
The #ASH25 virtual platform is now live! Log in now using the ASH username and password you used to register for the annual meeting:
https://ow.ly/MmlR50XBiMT
#ASH25
🌟Your bonus and preview content await. Plus, explore networking, exhibits, and more on the virtual platform!
#HemeSky
#MedSky
0
4
1
reposted by
Nico Gagelmann
American Society of Hematology
12 days ago
Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily. Read now:
https://ow.ly/tEgJ50XxAP6
#ASH25
#ASHNewsDaily
#HemeSky
#ASHaiku
#ASHKudos
#ASHRunWalk
#ASHScavengerHunt
1
9
3
reposted by
Nico Gagelmann
American Society of Hematology
10 days ago
The ASH annual meeting is the premier venue for #hematology collaborations across borders 🌏 #ASHThrowback to a meeting with ASH and the Mediterranean Partner Societies at #ASH24.
Belinda Avalos, MD
#hematology
#ASHThrowback
#ASH24
#ASH25
International community, share your throwbacks from past ASH meetings!
#HemeSky
0
6
2
Finally in Boston! Honored to join
@danafarber.bsky.social
, eager to learn and contribute in this terrific community
@coleman-lindsley.bsky.social
. A place of science, purpose and hope.
about 2 months ago
1
3
0
Thank you all who made COSTEM 2025 THE event for transplant & cellular therapies❗️ Faculty who fight REAL debates Audience that ask REAL questions Unity amid controversy🙏 See you 1-3 October 2026 in Berlin again!
2 months ago
0
0
0
Last Call for Early Bird Registration Join us at the 10th COSTEM Congress! 🗓️ September 25–28, 2025 📍 Berlin, Germany Don't miss your chance to save – Early Bird registration closes July 31st!
costem.cme-congresses.com/registration/
loading . . .
Registration - COSTEM Congress 2025
Registration for COSTEM 2025
https://costem.cme-congresses.com/registration/
4 months ago
0
0
0
reposted by
Nico Gagelmann
VJHemOnc
10 months ago
🎥 Check out our recent interview from
#CART25
with
@nicogagelmann.bsky.social
, in which he highlights the need to address inequality & inequity in access to
#CARTCell
therapy across Europe: 👉
buff.ly/4gBhWeD
#ImmunoOnc
#HemOnc
#Hematology
#MedSky
#BloodSky
#HemeSky
0
5
1
reposted by
Nico Gagelmann
Nihar Desai MD, DM
10 months ago
Out now in Blood Advances 🙌🏽 Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation! Also read this excellent commentary by my good friend
@nicogagelmann.bsky.social
👇🏽
ashpublications.org/bloodadvance...
0
8
4
MAKE CAR-T AFFORDABLE AGAIN Terrific learning experience from cellular therapy programs in India, Slovenia, Brazil and Turkey
#CART25
10 months ago
0
1
0
Let's learn hematology in 2025🩸 Day 27: hemophilia characteristics
10 months ago
0
1
0
🎉Finally published🎉 Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma
@hemasphere-journal.bsky.social
onlinelibrary.wiley.com/doi/full/10....
loading . . .
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Levera...
https://onlinelibrary.wiley.com/doi/full/10.1002/hem3.70070
11 months ago
1
9
1
reposted by
Nico Gagelmann
🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
loading . . .
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
https://www.nejm.org/doi/full/10.1056/NEJMoa2408941
11 months ago
0
11
5
reposted by
Nico Gagelmann
NEJM.org
11 months ago
In a single-group, single-center study, clearance of driver mutations 30 days after bone marrow transplantation predicted long-term disease-free survival in patients with myelofibrosis. Read the full study results:
nej.md/4fQNdKn
#MedSky
loading . . .
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
https://nej.md/4fQNdKn
0
16
5
reposted by
Nico Gagelmann
Amir Toor
11 months ago
www.nejm.org/doi/full/10....
loading . . .
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
https://www.nejm.org/doi/full/10.1056/NEJMoa2408941
0
1
1
reposted by
Nico Gagelmann
11 months ago
loading . . .
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
https://www.nejm.org/doi/full/10.1056/NEJMoa2408941
0
7
3
reposted by
Nico Gagelmann
NEJM.org
11 months ago
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study)
nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study)
nej.md/4fQNdKn
1
4
2
reposted by
Nico Gagelmann
Anand Patel
11 months ago
a blockbuster paper by
@nicogagelmann.bsky.social
et al in
@nejm.org
on the impact of driver mutation clearance in patients with MF that underwent allo-HCT!
www.nejm.org/doi/full/10....
2
8
4
🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
loading . . .
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
https://www.nejm.org/doi/full/10.1056/NEJMoa2408941
11 months ago
0
11
5
reposted by
Nico Gagelmann
American Society of Hematology
12 months ago
@nicogagelmann.bsky.social
1
5
1
reposted by
Nico Gagelmann
American Society of Hematology
12 months ago
#ASHKudos
for the award. Glad that you had fun at
#ASH24
!
0
4
1
What a wonderful
#ASH24
Honored to receive
@ash-hematology.bsky.social
Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego. Until next year 🙏🩸❤️
12 months ago
1
8
0
reposted by
Nico Gagelmann
VJHemOnc
12 months ago
Tomorrow
@nicogagelmann.bsky.social
will take over our Twitter account, bringing you live updates & expert takes straight from
#ASH24
🗞️🩸📱 Give us a follow over there so you don't miss the action 👉
x.com/VJHemOnc
👀
1
1
1
reposted by
Nico Gagelmann
Anand Patel
12 months ago
Now
@nicogagelmann.bsky.social
on molecular genetics and JAKi impact on allo-HCT in MF -1800 rux treated pts -early allo in high-risk PMF and SMF seems to be best timing -early allo in TP53 may offer survival benefit
1
5
2
🎉Finally out and timely for
#ASH24
@ash-hematology.bsky.social
🎉 Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple
#myeloma
#mmsm
t.co/F7QjOoavKO
loading . . .
https://www.nature.com/articles/s41408-024-01197-2
https://t.co/F7QjOoavKO
about 1 year ago
0
6
1
Happy to present first European comparison of cilta-cel vs ide-cel for
#myeloma
#ASH24
: -Cilta-cel with better ORR, CR, PFS -Similar NRM -Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel 👉associated with response and with ICANS for cilta-cel
@ash-hematology.bsky.social
about 1 year ago
0
5
0
reposted by
Nico Gagelmann
Ajay Major, MD, MBA
about 1 year ago
Honored to be featured on the
@ash-hematology.bsky.social
ASH News Daily
#ASH24
follow list! I'll be posting on both my Twitter (
https://buff.ly/3Zy7BLc
) and BS (
https://buff.ly/3B9SpKU
), so please do follow!
https://buff.ly/49iWb1d
1
9
1
reposted by
Nico Gagelmann
Ajay Major, MD, MBA
about 1 year ago
cc
@rahulbanerjeemd.bsky.social
@shematologist.bsky.social
@nicogagelmann.bsky.social
1
3
1
#ASH24
of the day: Talquetamab Bridging before CAR-T -Talq bridging: 62% ORR (14% CR) -Post-CAR-T: 97.5% ORR (35% CR) -Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS) -Post-CAR-T: less CRS (65%), ICANS (2% grade 3) Should be standard of care
#mmsm
@ash-hematology.bsky.social
about 1 year ago
0
4
2
reposted by
Nico Gagelmann
American Society of Hematology
about 1 year ago
🌟 Attention trainees! ASH-a-Palooza is just one week away! There’s still time to register for this trainee-focused party full of beats, free bites, & burst of learning. Kicking off
#ASH24
next Friday! Register:
bit.ly/ASH-a-Palooza
#ASHTrainee
#HemeSky
#Hematology
#Fellow
#MedSky
#HemeOnc
0
18
8
That escalated quickly
about 1 year ago
0
0
0
This platform is also the place to share and circulate: Donate blood🙏🩸 Donate stem cells🙏🩸 It doesnt hurt and save lives. Be a hero, in the real world. Be a hero here, and spread the word.
#donate
#medsky
#bmtsm
about 1 year ago
0
6
0
Science and medicine should NEVER EVER mix with politics🙏
about 1 year ago
0
2
0
20 people work for
@bsky.app
in Seattle. These 20 people ensure freedom of communication🤣🤣
about 1 year ago
0
1
0
The world needs resonance, not following not likes. Real engagement is what makes the world a better place and helps you find real friends.
about 1 year ago
0
4
0
reposted by
Nico Gagelmann
Nihar Desai MD, DM
about 1 year ago
Elon with Twitter!
@nicogagelmann.bsky.social
@drneilstone.bsky.social
0
0
1
Why did the platelet bring a date to the clot? Because it didn’t want to stick around alone!
add a skeleton here at some point
about 1 year ago
0
1
0
reposted by
Nico Gagelmann
Dr Neil Stone
about 1 year ago
I have a meropenem joke but I won't let you use it
add a skeleton here at some point
1
20
5
Follow me on
#Bluesky
because the future deserves your good taste in people🤣
about 1 year ago
0
1
0
I was going to tell you a chemistry joke, but I didn’t think it would get a reaction.
add a skeleton here at some point
about 1 year ago
0
6
2
reposted by
Nico Gagelmann
American Society of Hematology
about 1 year ago
Hello,
#hematology
community! ASH is now on BlueSky. We're here to share cutting-edge research and educational resources and connect global experts in blood diseases. Join us in advancing hematology together. Welcome, colleagues!
#BloodSky
#HemeSky
#MedSky
3
88
20
reposted by
Nico Gagelmann
Bruce Levine, Ph.D. 🇺🇦
about 1 year ago
Bluesky is the new destination for X/Twitter’s health and science community. Here’s why
#MedSky
#ScienceSky
🥼🧪https://www.statnews.com/2024/11/21/bluesky-gains-twitter-exodus-science-medical-community-finds-alternative-to-x/
loading . . .
Bluesky is the new destination for X/Twitter’s health and science community. Here's why
#MedTwitter is migrating en masse from X to Bluesky, suddenly making it an essential hub for scientific discourse. Here's why.
https://www.statnews.com/2024/11/21/bluesky-gains-twitter-exodus-science-medical-community-finds-alternative-to-x/
0
16
3
reposted by
Nico Gagelmann
Nihar Desai MD, DM
about 1 year ago
🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to
@haemophage.bsky.social
for his mentorship 🙌🏼
doi.org/10.1182/bloo...
#MedSky
#HemeSky
4
37
13
Imagine that...
about 1 year ago
0
1
1
Donate blood and stem cells🙏 It doesnt hurt and you save a life. Register now
@dkms-de.bsky.social
or others🩸
about 1 year ago
0
2
1
The reason why we are here
about 1 year ago
0
3
0
reposted by
Nico Gagelmann
Shematologist, MD
about 1 year ago
Every single day I’m on service, no matter how tough it is, I remind myself that I get to go home and my babies are there and we all have our health and aren’t staying the night in the hospital. Perspective is everything.
10
286
15
First rule of academia: God is called "The Deadline"
about 1 year ago
0
1
1
Finally out🎉 Role of molecular alterations in transplant decision for primary myelofibrosis Wonderful international collaboration
#medskey
ashpublications.org/bloodadvance...
loading . . .
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis
Key Points. MIPSS70 high patients benefit from transplantationMIPSS70 intermediate patient may benefit from transplantation if their MTSS score is low or i
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024014368/526013/Role-of-molecular-alterations-in-transplantation
about 1 year ago
0
0
0
Invest in the future, not the present, not the past!
about 1 year ago
0
2
0
Load more
feeds!
log in